DES (Diethylstilbestrol) Info

DES (Diethylstilbestrol) Info We welcome everyone from the DES community -- Mothers, Daughters, Sons, 3rd Generation and all exposed! In some clinics, it was given to every pregnant patient.

DES Info Association:

The DES tragedy of in-utero exposure and its devastating effects on multiple generations must not be forgotten. The medical community need education about the sequela of DES Exposure. (1) know how to screen the DES exposed, (2) Know the continueing long term effects of DES exposure, and (3) Provide prompt care when DES Exposed patients develop complications.

** What is DES (diethylstilbestrol)? **

DES (diethylstilbestrol), is a teratogenic and carcinogenic synthetic estrogen (Endocrine Disruptor) , is the world’s first major drug disaster. It was prescribed to millions of pregnant women for decades: from 1938 into the 1970s in the United States; and until the mid-1980s in parts of Latin America, Europe, Australia, and the Third World (Currently in Kenya). The currently proven effects of exposure include a rare vaginal cancer in DES Daughters; greater risk for breast cancer in DES Mothers; possible risk for testicular cancer in DES Sons, along with transgender and reproductive malformations; abnormal reproductive organs; infertility; high-risk pregnancies; Skeletal issues and an increased risk for breast cancer in DES Daughters. There are a number of other suspected effects, including auto-immune disorders, but many of these effects are still awaiting further research. For decades, Big Pharma claimed DES prevented miscarriages and problem pregnancies. It was sometimes given as an injection, but primarily it was prescribed in pill form. Never patented, DES was marketed under 200 different names, although the majority of the drug was actually produced by Eli Lilly. DES was sometimes even included in prescription prenatal vitamins. As early as 1938, studies showed that DES promoted cancer in lab animals. But at that time, people thought animal studies only provided a hint of what could happen in humans. Also, no one knew that drugs could cross the placenta and affect a baby in utero. (Note there was a 1941 mouse study that showed mice with absent or deformed fallopian tubes. The warning signs were there for humans.) In 1941, the original clinical uses for DES were to treat gonorrheal vaginitis, senile vaginitis, menopausal symptoms and to suppress lactation. Between 1941 and 1947, it was used for pregnancy without FDA approval. No controlled studies were ever conducted by the drug companies to determine the effectiveness or safety of DES for use during pregnancy, even after some scientists started questioning its efficacy in the 1950s. As early as 1953, research revealed that DES did not work (The Dieckmann Study) – that DES actually brought about higher rates of premature birth and infant mortality – yet DES continued to be prescribed to pregnant women for decades. This is because pharmaceutical companies continued to heavily promote DES use to doctors. The drug was a top moneymaker for Big Pharma. In the late 1960s, there was an unprecedented appearance of rare cancer in young women. Clear cell cancer (CCA) – a rare cancer of the vagina – was diagnosed in an age group never before found to develop it. (Normally elderly women developed CCA.) There were eight such cases at Massachusetts General Hospital in Boston alone. One of the mothers raised the question of whether her daughter's cancer might be connected to DES exposure in utero. Doctors discovered the DES link in 1971 and published their findings in the April 1971 issue of New England Journal of Medicine. News of the cancer cases made national headlines. However, the FDA did not act on this information until public pressure, including Congressional Hearings, forced the FDA to issue a warning about DES in November 1971. The drug was not banned for human use. DES was contraindicated for pregnancy by the FDA in 1972. It was not until September 2000 that the FDA finally withdrew its approval of DES for humans. Researchers are now investigating whether DES health issues are extending into the next generation, the so-called DES Grandchildren (Third Generation). As study results come in, there is growing evidence that this group has been adversely impacted by a drug prescribed to their grandmothers. To this day, not one drug company has ever apologized or accepted responsibility for the DES tragedy. Nevertheless, they have paid millions in out-of-court settlements and verdicts to DES Daughters and Sons who suffered injuries from their exposure. Please join us in our mission to continue to provide information to the DES exposed on DES information and other health related information along with pushing for more physician education to know how to care for the DES exposed. Also, we are continuing to push for more research! Our moto is "Knowledge is Power" DES Info Association is a free resource for Diethylstilbestrol Information and Research

“DISCLAIMER: THIS SITE DOES NOT PROVIDE MEDICAL ADVICE. The information on this site, including but not limited to text, graphics, images and other material, is for informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. If you have any questions about how the information contained on this website may relate to you, you should seek the advice of a physician or other qualified health care professional.”

DES Info: Did DES work.... the answer is NO but it caused a major tragedy!Diethylstilbestrol (DES) is a synthetic estrog...
01/07/2026

DES Info: Did DES work.... the answer is NO but it caused a major tragedy!

Diethylstilbestrol (DES) is a synthetic estrogen that was first manufactured in a laboratory in 1938, so it is called a “synthetic estrogen.”

Starting in 1938 and into the 1970s physicians prescribed DES to pregnant women to prevent miscarriages and avoid other pregnancy problems.

Physicians prescribed DES to pregnant women on the theory that miscarriages and premature births occurred because some pregnant women did not produce enough estrogen naturally. At the time, physicians thought DES was safe and would prevent miscarriages and pre-term (early) births.

In 1953, published research showed that DES did not prevent miscarriages or premature births.

■ “Does the administration of DES during pregnancy have therapeutic value” Dieckmann study at the University of Chicago concludes that DES "has no beneficial effect whatsoever on the prevention of miscarriage." This study was conducted using Eli Lilly’s DES pills. Approximately 800 pregnant women are given DES and 800 pregnant women are given a placebo. The women who took DES have more miscarriages and lower-weight babies. This was published in the DES was continued to be marketed because pharmaceutical companies discredited the study and continued to heavily promote this drug to physicians. (American Journal of Obstetrics & Gynecology Nov 1953 66 (5) Pages 1062 – 1080)

The DES Exposed are still awaiting an apology!



DESInfo411@gmail.com

DES Info: We are sharing this research article with you. It is important to understand how important the HOX Genes are a...
01/06/2026

DES Info: We are sharing this research article with you. It is important to understand how important the HOX Genes are and how DES affected them.

Du H, Taylor HS. “The Role of Hox Genes in Female Reproductive Tract Development, Adult Function, and Fertility.” Cold Spring Harb Perspect Med. 2015 Nov 9;6(1): a023002. doi: 10.1101/cshperspect.a023002. PMID: 26552702; PMCID: PMC4691806.

This research study concludes: “Diethylstilbestrol (DES) and other endocrine disruptors cause Müllerian defects by changing HOX gene expression. HOX genes are also essential regulators of adult endometrial development. Regulated HOXA10 and HOXA11 expression is necessary for endometrial receptivity; decreased HOXA10 or HOXA11 expression leads to decreased implantation rates.

“Alternation of HOXA10 and HOXA11 expression has been identified as a mechanism of the decreased implantation associated with endometriosis, polycystic ovarian syndrome, leiomyoma, polyps, adenomyosis, and hydrosalpinx.”

“Alteration of HOX gene expression causes both uterine developmental abnormalities and impaired adult endometrial development that prevent implantation and lead to female infertility.”

For further information, please review the article online or contact DES Info Association at DESInfo411@gmail.com. Please include the title of the article.


DES Info: DES dosages for mothers - I survived!  The Smith and Smith Regimen for DES 1953 Physician’s Desk Reference (PD...
01/03/2026

DES Info: DES dosages for mothers - I survived!

The Smith and Smith Regimen for DES

1953 Physician’s Desk Reference (PDR) Doctors George and Olive Smith:

The Smith and Smith Regime (Physicians from Harvard) advised the following regime for oral administration of DES:

Weeks of Pregnancy from first day of last menstrual period

Daily Dose
7th & 8th week 5 mg
9th & 10th week 10 mg
11th & 12th week 15 mg
13th & 14th week 20 mg
15th week 25 mg
16th week 30 mg
17th week 35 mg
18th week 40 mg
19th week 45 mg
20th week 50 mg
21st week 55 mg
22nd week 60 mg
23rd week 65 mg
24th week 70 mg
25th week 75 mg
26th week 80 mg
27th week 85 mg
28th week 90 mg
29th week 95 mg
30th week 100 mg
31st week 105 mg
32nd week 110 mg
33rd week 114 mg
34th week 120 mg
35th week 125 mg

I survived this exposure but what is my future? … It has not been an easy road with more health issues unfolding. Physicians are not aware of the many effects of in utero DES Exposure.

DES Info Association has published a pamphlet on the care of the DES Exposed. If you would like a copy, please email us a DESInfo411@gmail.com

The DES exposed are still awaiting an apology for this medical tragedy!



DESInfo411@gmail.com

We are back!Thank you for sharing.   For 2026 DES Awareness Week we will be publishing Second Edition Voices of the DES ...
01/02/2026

We are back!

Thank you for sharing.

For 2026 DES Awareness Week we will be publishing Second Edition Voices of the DES Exposed speaking out. Watch for our post.

12/24/2025
DES Info:  We are sharing with you this important Research Article on diethylstilbestrol exposure and cancer risk Import...
12/19/2025

DES Info: We are sharing with you this important Research Article on diethylstilbestrol exposure and cancer risk Important Study Results!

Troisi, R., Hatch, E.E., Titus, L., Strohsnitter, W., Gail, M.H., Huo, D., Adam, E., Robboy, S.J., Hyer, M., Hoover, R.N. and Palmer, J.R. (2019), “Prenatal diethylstilbestrol exposure and cancer risk in women.” Environ. Mol. Mutagen., 60: 395-403. https://doi.org/10.1002/em.22155

The study results are important and should be shared with your doctor:

“The excess risk of breast and pancreatic cancers that we observed is concerning and warrants continued follow-up and mechanistic investigation”

For further information, please review the article on line or contact DES Info Association: DESInfo411@gmail.com. Please include the title of the article..

In the Diethylstilbestrol [DES] Combined Cohort Follow-up, the age- and calendar-year specific standardized incidence ratio [SIR] for clear cell adenocarcinoma [CCA] was 27.6 (95% confidence interval...

DES Info: DES - Uterine Leiomyoma Genes   We are sharing with you a research study that identified specific genes.Greath...
12/17/2025

DES Info: DES - Uterine Leiomyoma Genes We are sharing with you a research study that identified specific genes.

Greathouse KL, Cook JD, Lin K, Davis BJ, Berry TD, Bredfeldt TG, Walker CL.” Identification of uterine leiomyoma genes developmentally reprogrammed by neonatal exposure to diethylstilbestrol.” Reprod Sci. 2008 Oct;15(8):765-78. doi: 10.1177/1933719108322440. PMID: 19017814.

This study was conducted on the mouse model and identified specific genes altered by DES. “Calbindin D9k and Dio2, normally induced by estrogen, exhibited elevated expression in DES-exposed animals during both phases of the estrus cycle. Gdf10, Car8, Gria2, and Mmp3, genes normally repressed by estrogen, exhibited elevated expression in DES-exposed animals during the proliferative phase, when estrogen is highest."

For further information, please review the article online or contact DES Info Association at DESInfo411@gmail.com. Please include the title of the article.



DESInfo411@gmail.com

DES Info: We are sharing with you a research article on tumors in 2nd generation DES Sons and AbnormalitiesTurusov VS, T...
12/17/2025

DES Info: We are sharing with you a research article on tumors in 2nd generation DES Sons and Abnormalities

Turusov VS, Trukhanova LS, Parfenov YuD, Tomatis L. “Occurrence of tumours in the descendants of CBA male mice prenatally treated with diethylstilbestrol”. Int J Cancer. 1992 Jan 2;50(1):131-5. doi: 10.1002/ijc.2910500126. PMID: 1728603.

This research was in the mouse model which has been a good model to study the effects of DES: The study concludes with the following: “The increased cancer risk has been reported to persist in the second-generation descendants of DES-exposed pregnant mice. In the female offspring so obtained, but not in the male, a statistically significant increased incidence of tumors was observed, in particular of uterine sarcomas, and also of benign ovarian tumors and of lymphomas.”

For further information, please review the article or contact DES Info Association: DESInfo411@gmail.com. Please include the title of the article.

DES Info: We are sharing with you this important study results that discusses exposure and cancer risk Important Study R...
12/15/2025

DES Info: We are sharing with you this important study results that discusses exposure and cancer risk Important Study Results!!!

Troisi, R., Hatch, E. E., Titus, L., Strohsnitter, W., Gail, M. H., Huo, D., ... & Palmer, J. R. (2019). “Prenatal diethylstilbestrol exposure and cancer risk in women”.

Environmental and Molecular Mutagenesis, 60(5), 395-403.
We need to pay attention and our physicians need to know about these risks:

“Risks for Clear Cell Adenocarcinoma, breast cancer, and now pancreatic cancer. The excess risk of breast and pancreatic cancers that we observed is concerning and warrants continued follow-up and mechanistic investigation.”

DES Info: This is important information and consider sharing it with your physician. This is included in the new DES Pamphlet. Please email us at DESInfo411@gmail.com if you would like a copy.

DES Info: Gene Alteration – HOXA GenesBromer JG, Wu J, Zhou Y, Taylor HS. “Hypermethylation of homeobox A10 by in utero ...
12/10/2025

DES Info: Gene Alteration – HOXA Genes

Bromer JG, Wu J, Zhou Y, Taylor HS. “Hypermethylation of homeobox A10 by in utero diethylstilbestrol exposure: an epigenetic mechanism for altered developmental programming.” Endocrinology. 2009 Jul;150(7):3376-82. doi: 10.1210/en.2009-0071. Epub 2009 Mar 19. PMID: 19299448; PMCID: PMC2703508.

This is an important study because the HOXA genes were altered by DES Exposure.
This study concludes with the following:
“DES has a dual mechanism of action as an endocrine disruptor; DES functions as a classical estrogen and directly stimulates HOXA10 expression with short-term exposure, however, in utero exposure results in hypermethylation of the HOXA10 gene and long-term altered HOXA10 expression. We identify hypermethylation as a novel mechanism of DES-induced altered developmental programming.”

DES Info: These genetic mutations are important…more research is needed!
For further information, please review the article online or contact DES Info Association at DESInfo411@gmail.com. Please include the title of the article.



DESInfo411@gmail.com

DES Info: We are sharing with you a research article on DES & the increased risk of breast cancerHilakivi-Clarke L. “Mat...
12/10/2025

DES Info: We are sharing with you a research article on DES & the increased risk of breast cancer

Hilakivi-Clarke L. “Maternal exposure to diethylstilbestrol during pregnancy and increased breast cancer risk in daughters.” Breast Cancer Res. 2014;16(2):208. doi: 10.1186/bcr3649. PMID: 25032259; PMCID: PMC4053091.

In this research article one of the researchers shares the following: "We know from human studies that daughters whose mothers took the synthetic estrogen diethylstilbestrol (DES) to reduce pregnancy complications, or who had a birth weight of more than 8.8 pounds are at an increased risk of developing breast cancer. Our study suggests their offspring may also be at risk," Hilakivi-Clarke says.

"This study suggests directions for future research in women. Could a woman's susceptibility to breast cancer development be determined by what her grandmother ate when she was pregnant, or if she was exposed to high levels of estrogen — perhaps unwittingly, through the environment?" asks de Assis.

For further information, please review the article on line or contact DES Info Association: DESInfo411@gmail.com. Please include the title of the article.



DESInfo411@gmail.com

Address

Dallas, TX

Telephone

+19728208400

Website

https://www.cancer.gov/about-cancer/causes-prevention/risk/hormones/des-fact-sheet,

Alerts

Be the first to know and let us send you an email when DES (Diethylstilbestrol) Info posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to DES (Diethylstilbestrol) Info:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram